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Researchers at Memorial Sloan-Kettering Cancer Center have investigated many aspects of their experience with ductal carcinoma
in situ of the breast over the past 20years. This paper summarizes the most clinically relevant ﬁndings.
1.Introduction
Since its founding in 1884 as the New York Cancer Hospital,
Memorial Sloan-Kettering Cancer Center (MSKCC) in New
York, NY, has concentrated its clinical and research eﬀorts
on the diagnosis and management of cancer. This review
summarizes MSKCC’s work on ductal carcinoma in situ
(DCIS) of the breast.
2.Mammographic Featuresof DCIS and
Its Recurrences
In the late 1980s and early 1990s, increasing screening
mammography resulted in increasing detection of clinically
occult carcinomas, including DCIS. From 1973 to 1992,
the incidence of DCIS increased by 557%, from 2.4 to
15.8 per 100,000 women [1]. Prior to widespread screening
mammography, DCIS constituted 0.8% to 5.0% of all breast
carcinomas; by 1996 it constituted 14% [2, 3].
In these early days, when the diagnosis of DCIS was
exponentially increasing, Dershaw et al. attempted to deﬁne
the mammographic features of DCIS. They retrospectively
reviewed mammograms, specimen radiographs, and pathol-
ogy reports for 51 patients with DCIS treated in the 1980s
[4].DCISwasradiographicallyevidentasmicrocalciﬁcations
alone in 68% and as microcalciﬁcations within a mass
in 30%. Several radiographic ﬁndings indicated multifocal
disease: mass larger than 2.5cm; more than one mass;
more than one cluster of microcalciﬁcations; or parallel
linear intraductal calciﬁcations. This work demonstrated
thatintheoverwhelmingmajorityofpatients,DCISpresents
as mammographically evident microcalciﬁcations and that
speciﬁc mammographic ﬁndings may suggest multifocal
disease.
During the 1980s and 1990s, breast surgery for DCIS
became progressively less invasive. No randomized trial
was ever performed comparing breast conservation to
mastectomy for DCIS. However, as results from Fisher et
al. [5] and Veronesi et al. [6], which proved that breast-
conserving surgery (BCS) plus radiation was equivalent to
total mastectomy (TM) for invasive cancer, were assimilated,
it was assumed that the same ﬁndings would hold for DCIS.
In 1983, 71% of patients with DCIS were treated with TM,
and by 1992, only 44% were [1].
TM eliminates the need for postoperative screen-
ing mammography; BCS does not—the remaining breast
requires continued surveillance for ipsilateral breast tumor
recurrences (IBTRs). This was the focus of investigation of
Liberman et al. [7]. They performed a retrospective review
of 162 patients treated with BCS for DCIS between 1978
and 1990. Median follow-up was 75 months (range, 3–210
months). Thirty-three (20%) were diagnosed with IBTRs;
of these, mammograms were available for review in 20.
Median time to IBTR was 26 months (range, 6–168 months);2 International Journal of Surgical Oncology
IBTRs were DCIS-only in 13 (65%), and in-situ and invasive
ductal carcinoma in 7 (35%). They found that: (1) 95%
of IBTRs were mammographically evident (85% detectable
only mammographically; 10% detectable mammographi-
cally and by palpation; 5% detectable only by palpation);
(2) IBTRs were mammographically evident whether they
were DCIS or invasive; and (3) 90% of IBTRs demonstrated
calciﬁcations, of which 79% demonstrated a mammographic
pattern identical to the primary tumor (clustered versus
linear versus multiple versus regional versus segmental), and
of which 82% demonstrated a mammographic morphology
identical to the primary tumor (linear versus pleomorphic
versus punctate). Liberman et al. deﬁnitively demonstrated
that mammography can detect IBTRs in patients who
u n d e r g oB C Sf o rD C I S .
3.SentinelLymphNode Metastasis
in Patientswith DCIS: Incidenceand
ClinicalImplications
Cody et al. [8] and Cody and Van Zee [9] ask: “Is axillary
node staging required in patients with DCIS of the breast?”
Its nomenclature would suggest that DCIS is incapable
of breaking through the ductal basement membrane, of
accessing breast parenchyma or lymphatic channels, and of
spreading locally, regionally, or distantly. In fact, Lagios and
Silverstein argue that sentinel lymph node biopsy (SLNB) is
“dangerous and unwarranted” in the setting of DCIS [10].
They are correct: searching for metastatic spread of a lesion
that is by deﬁnition incapable of metastatic spread may
yield potential problems—one may ﬁnd nothing, thereby
wasting eﬀort, time, and health care resources, or one may
induceharmbycausingmorbidity,includingthemostfeared
complication of axillary surgery: lymphedema [11, 12]. In a
sense, Cody and Van Zee agree with Lagios and Silverstein.
They argue that “the strongest argument for sentinel lymph
node (SLN) biopsy in DCIS is the diagnostic uncertainty
and inherent sampling error of conventional pathologic
techniques. SLN biopsy is indicated in any DCIS patient who
may have an underlying invasive cancer, especially those who
require mastectomy” [9]. Two studies from MSKCC attempt
to evaluate these arguments.
Klauber-DeMore et al. performed a clinical audit of
76 patients with DCIS and 38 patients with DCIS with
microinvasion (DCIS-MI), all of whom underwent SLNB
between 1997 and 1999 [13]. “Patients with DCIS were
consideredtobeathighriskandwereselectedforSLNbiopsy
if there was suﬃc i e n tc o n c e r nt h a ta ni n v a s i v ec o m p o n e n t
would be identiﬁed in the specimen during the deﬁnitive
surgery.”Thesehigh-riskpatientshadapalpablemass(21%),
mammographic mass (34%), histology suspicious but not
diagnostic for microinvasion (24%), multicentric disease
requiring TM (53%), or high nuclear grade or non-high
nuclear grade with necrosis (72%). DCIS-MI was in and of
itself high-risk.
For patients with DCIS, 9 (12%) had a positive SLN.
Seven of these patients had isolated tumor cells positive only
by immunohistochemistry—what is currently categorized as
pN0(i+) according to the subsequently revised American
Joint Commission on Cancer (AJCC) staging system, 6th
Edition (2002) and 7th Edition (2010). Upon completion
axillary lymph node dissection, 1 patient had additional
macrometastasis (>2mm) positive by routine hematoxylin
and eosin (H&E). These ﬁndings prompted re-evaluation
of primary-tumor specimens. One patient had a focus of
microinvasion, one patient had a metastatic invasive carci-
noma of the contralateral breast, and 2 patients had lympho-
vascular invasion despite no evidence of stromal invasion.
For patients with DCIS-MI, 3 (10%) had a positive
SLN: one macrometastasis positive by routine H&E; one
micrometastasis positive by routine H&E and immunohis-
tochemistry; and one with isolated tumor cells positive by
immunohistochemistry. Upon completion axillary lymph
node dissection, no further positive nodes were found. Re-
evaluation of primary-tumor specimens revealed invasion
greater than 1mm in 2 patients, changing the tumor status
from Tis to T1mi. Furthermore, one of these patients
demonstrated in-breast lymphatic invasion.
Klauber-DeMoreetal.demonstratedthatthefrequencies
of positive axillary SLNs, including isolated tumor cells in
patients with DCIS in whom the surgeon was concerned
that invasion was present and in patients with DCIS-MI,
were 12% and 10%, respectively [13]. Moore et al. sought
to evaluate the clinical relevance of such involvement [14].
Between 1994 and 2002, 2159 patients underwent surgery
for DCIS at MSKCC, the John Wayne Cancer Institute, or
the University of Southern California. Of these, 470 patients
underwent SLNB. As in the previous report, for the most
part, these patients had high-risk DCIS.
Forty-three (9%) had a positive SLN. Of these, 3 (7%)
had macrometastases, 4 (9%) had micrometastases, and 36
(84%) had isolated tumor cells. Re-evaluation of primary-
tumor specimens demonstrated that 2 (5%) had DCIS-MI
and 2 (5%) had lymphovascular invasion. Ultimately, 9 of
43 (21%) high-risk DCIS patients with a positive SLN, and
9 of 470 (2%) of all high-risk DCIS patients were upstaged
to stage 1 or stage 2 (AJCC 6th Edition) as a direct result of
SLNB. Based on these ﬁndings, 16 patients (37%) received
chemotherapy. At median follow-up of 27 months (range,
3–88 months), one patient with isolated tumor cells in her
SLN developed hepatic metastases and died of disease. Re-
evaluation of her primary-tumor specimen demonstrated
previously unidentiﬁed microinvasion. Finally, Moore et al.
found 2 factors associated with SLN positivity for patients
with DCIS: extensive disease requiring mastectomy (12%
versus 4%, P = 0.016) and presence of necrosis (11% versus
3%, P = 0.04).
In summary, these 2 reports conclude that approximately
1 of 10 patients with high-risk DCIS or DCIS-MI have
evidence of axillary metastases on SLNB, including macro-
or micrometastases, and isolated tumor cells. And of these,
only about 20% are considered upstaged according to the
AJCC 6th Edition staging system (and 26% according to the
AJCC 7th Edition staging system). Therefore, only about 2%
of all women with high-risk DCIS or DCIS-MI are upstaged
due to SLN ﬁndings. In conclusion, while SLNB should
not be routinely used for DCIS, it is appropriate in womenInternational Journal of Surgical Oncology 3
undergoing TM or in women in whom the suspicion of
invasive carcinoma is high.
4. Utility of Preoperative MRI for
Paget’s Disease of the Breast
Paget’s disease of the breast usually presents with eczematous
changes of the nipple-areola complex, such as erythema,
scaling, and itching [15]. In-situ or invasive carcinoma
usually underlies these epidermal changes [16]. Thus, upon
clinical or pathologic diagnosis, breast imaging is pursued
in an eﬀort to characterize the extent of the underlying
associated cancer. Mammography has been the mainstay of
radiologic work-up. Morrogh et al. sought to evaluate the
utility of MRI as a complementary imaging modality [17].
The authors retrospectively reviewed the charts of 34
patients who presented between 1995 and 2005 with changes
in the nipple-areola complex consistent with Paget’s disease
[17]. Patients with a prior history of ipsilateral breast
carcinoma were excluded. All 34 patients underwent pre-
operative mammography; 13 underwent preoperative MRI.
All underwent surgery, and, on ﬁnal pathology, 32 of 34
patients(94%)hadanunderlyingcancer(DCIS,56%;DCIS-
MI, 18%; invasion, 21%) and 2 of 34 patients (6%) had an
underlyingbenignlesion(atypicalductalhyperplasia,3%;or
intraductal papilloma, 3%).
Preoperative mammography identiﬁed 11 of 32 (34%)
cancers, accurately demonstrating extent of disease in 9.
Among the 13 women who underwent MRI, MRI identiﬁed
7 of 12 (58%) cancers, accurately demonstrating extent
of disease in 6. After a positive mammogram, subsequent
MRI did not alter course of treatment. However, after a
negative mammogram, subsequent MRI detected otherwise-
occult disease in 4 of 8 patients, accurately demonstrating
extent of disease in all. Overall, mammography had 100%
positive predictive value, 9% negative predictive value, 34%
sensitivity, and 100% speciﬁcity, while MRI had 100%
positive predictive value, 17% negative predictive value, 58%
sensitivity, and 100% speciﬁcity.
In this series, there was no beneﬁt of MRI in patients
with positive mammography. However, in patients with
negative mammography, MRI demonstrated an underlying
occult cancer and the extent of that cancer in about half, thus
providing a diagnosis and facilitating surgical treatment.
The ability to determine extent of disease was tantamount,
for it enabled the surgeon to determine the feasibility of
BCS. In this study, 59% of patients had disease conﬁned to
the central part of the breast. Thus for patients with Paget’s
disease of the breast and a negative mammogram, MRI
is helpful in detecting the presence and extent of occult,
underlying carcinomas.
5.Age: AssociationswithLocal
RecurrenceofDCISandwithDCISTreatment
Practice Patterns
Early after the publication of randomized studies proving
the equivalency of BCS with adjuvant radiotherapy and
TM for invasive carcinoma, clinicians and patients slowly
adopted BCS for DCIS. Van Zee et al. investigated MSKCC’s
early experience with BCS for DCIS [18]. They performed
a retrospective analysis of 157 patients with DCIS treated
with BCS between 1978 and 1990 with a median follow-up
of74months.Of157patients,33(21%)werediagnosedwith
IBTRs. The actuarial IBTR rate was 16.1% at 6 years. Among
those who received radiotherapy, the 6-year IBTR rate was
9.6%; without radiotherapy, it was 20.7% (P = 0.05). On
univariateanalysis,clinicopathologicfeaturesassociatedwith
lower IBTR rates were older age, noncomedo subtype, lower
nuclear grade, negative margins, and adjuvant radiotherapy.
For patients less than 40 years old, the 6-year IBTR rate
was 47.2%; for patients 40–69 years old, the 6-year IBTR
rate was 14.0%; for patients 70 years old or greater, the 6-
year IBTR rate was 10.8%. Compared to younger patients,
lower IBTR rates were seen in older patients whether
adjuvant radiotherapy was used or not. IBTR rates with and
without radiotherapy for the 3 age groups were <40 years
old: 33.3% and 59.2%; 40–69 years old: 8.5% and 19.1%;
≥70 years old: 0.0% and 14.4%, respectively. Compared to
younger patients, older patients tended to have lower nuclear
grades and were less likely to receive adjuvant radiotherapy,
but no factor (including clinical presentation, tumor size,
comedo subtype, nuclear grade, presence of necrosis, margin
status, or adjuvant radiotherapy) demonstrated a statistically
signiﬁcant association with age. This study showed that
compared to older patients, younger patients treated with
BCS for DCIS are more likely to develop IBTRs and that they
are at a relatively high risk for IBTRs.
This ﬁnding, which had not been previously shown
for DCIS, has also been observed by Veronesi et al. for
invasive carcinoma. He found that women who underwent
quadrantectomy alone for invasive carcinomas had an IBTR
rate of 17.5% if they were 45 years of age or younger, and
3.8% if they were 55 years of age or older [19]. Veronesi
et al. surmised that with age, “the complex structure of the
mammary gland disappears and the breast is reduced to a
fatty organ with scattered islands of ﬁbroepithelial tissue,
without connections between them.”
BCS attempts to balance oncologic and cosmetic
imperatives—to treat cancer while maintaining the size and
shape of the native breast. Ideally, a surgeon excises a
primary tumor to clear margins and leaves as much normal
tissue intact as possible. In a sense, TM allows for the
biggest possible margin and, in doing so, achieves oncologic
imperatives, but pays the cosmetic price of complete removal
of the breast. Conversely, a limited tumorectomy allows
for the smallest possible margin and, in doing so, achieves
cosmetic imperatives, but is associated with higher rates
of IBTR. This may have been particularly true prior to
the 1980s, when diligent microscopic assessment of inked
margins was not standard.
Hwang et al. postulated that volume of surgical resection
may be related to age, which at least partially explains
the observation that older women have lower IBTR rates
compared to younger women [18, 20]. Older women tend
to have higher BMIs and larger breasts, perhaps allowing
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possiblethattheoncologic-cosmeticbalanceofBCSistipped
toward wider margins and away from cosmesis in older
patients compared to younger patients.
Hwang et al. hypothesized that surgeons were more
willing to take larger volumes of tissue in older patients
compared to younger patients, increasing IBTR-free survival
but possibly compromising cosmesis. They retrospectively
reviewed the same population studied by Van Zee et al.
and found 126 cases with available information regarding
the volume of resection. They found that while tumor size,
margin status, histologic subtype, nuclear grade, and size
did not correlate with volume of resection, patient age
did—younger patients had signiﬁcantly smaller volumes of
resection than older patients (P = 0.03). Patients with
smaller volumes of resection had higher 6-year IBTR rates
than patients with larger volumes of resection (21% versus
5.6%; P = 0.16). Also, patients with smaller volumes of
resection were more likely to undergo adjuvant radiotherapy
than patients with larger volumes of resection, though both
groups beneﬁted. For the small volume-of-resection group,
the IBTR rate was 12.7% with adjuvant radiotherapy and
29.1% without adjuvant radiotherapy. For the large volume-
of-resection group, the IBTR rate was 0% with adjuvant
radiotherapy and 7.1% without adjuvant radiotherapy.
In summary, Hwang et al. conclude that older patients
tend to have larger volumes of resection, which is associated
with lower rates of IBTR, even in the absence of adjuvant
radiotherapy. There are 3 possible reasons for this. First,
“smaller resection volumes may be used in younger patients
to achieve a better cosmetic result, possibly contributing to
ah i g hl o c a lr e c u r r e n c e ”[ 20], showing that the oncologic-
cosmetic balance is tipped away from oncologic imperatives
toward cosmetic ones. This had been suggested by the Joint
CenterforRadiationTherapyforwomenwithinvasivebreast
cancer [21]. Second, as stated previously, in older patients,
“the complex structure of the mammary gland disappears
and the breast is reduced to a fatty organ with scattered
islandsofﬁbroepithelialtissue,withoutconnectionsbetween
them” [19]; the older breast is anatomically and physiolog-
ically less likely to have a diﬀuse distribution of DCIS and
therefore less prone to have unresected microscopic disease.
Third, the biology of breast cancer in younger patients
is intrinsically more aggressive than the biology of breast
cancer in older patients; compared to younger patients, older
patients tend to have low nuclear grades and hormone-
receptor positivity [20, 22, 23].
Ho et al. expand upon the aforementioned works by Van
Zee et al. and Hwang et al. [18, 20] and “aimed to determine
the impact of increasing age and other clinicopathologic
featuresontreatmentpatternsandoutcomesinolderwomen
with DCIS” [24]. The analysis of Van Zee et al. included 157
patients (of any age) treated with BCS for DCIS over a 12-
year period. The analysis of Ho et al. included 646 patients
(60 years of age or older) treated between 2000 and 2007 (2
decades after those studied by Van Zee et al. and Hwang et
al.), of whom over 75% underwent BCS. Though reasons
for this increase are certainly multiple, it is clear that over
the past 20 years, widespread screening mammography has
resulted in more frequent detection of DCIS and that more
and more patients are being treated with BCS than with TM.
Ho et al. included646patients,despiterestrictingtheirstudy
population to those 60 years old or older. This supports the
notion that the United States population at large, and cancer
patients in particular, are aging. In 2010, 25,000 women
65 years of age or older were diagnosed with DCIS; it is
estimated that, in 2030, 39,000 women 65 years old or older
will be diagnosed with DCIS, a 56% increase [25].
Ho et al. found that even among older patients, the
oldest received less aggressive therapy—for patients aged
60–69 years, 45% received TM, 25% received BCS with
radiotherapy, and 30% received BCS alone; for patients aged
70–79 years, 38% received TM, 20% received BCS with
radiotherapy, and 40% received BCS alone; for patients aged
80 years or more, 16% received TM, 13% received BCS with
radiotherapy, and 71% received BCS alone (P<0.001).
In addition to younger age (P<0.001), higher grade
(P<0.001) and the presence of necrosis (P<0.01) were
associated with TM or radiotherapy.
Median follow-up was 54 months (range, 6–112
months). The 4-year local recurrence rate was 3.6% and
diﬀered according to treatment. None of the TM group,
4% of the BCS-radiotherapy group, and 5% of the BCS-
a l o n eg r o u pe x p e r i e n c e dal o c a lr e c u r r e n c ea t4y e a r s( P<
0.005). When the BCS-radiotherapy and BCS-alone groups
werecompared,nostatisticallysigniﬁcantdiﬀerencesinlocal
recurrence were detected (P = 0.66). Besides treatment,
no other factors—including age—were associated with local
recurrence.
The study of Ho et al. is neither randomized nor
controlled. Rather, it is a clinical audit; its data are the
end-resultsofinnumerableindividualizedmedicaldecisions.
Most patients with BCS did not receive radiotherapy in spite
of data from 4 randomized controlled trials that deﬁnitively
show a lower IBTR rate among those that receive adjuvant
radiotherapy [26–29]. Nonetheless, the omission of adjuvant
radiotherapy did not translate into substantially diﬀerent
IBTR rates, at least in this patient population. That older
women were less likely to experience an IBTR—despite not
undergoing adjuvant radiotherapy—suggests that clinicians
are able to individualize treatment appropriately. These
ﬁndings also demonstrate that, in the current era, older
women have lower rates of IBTR, conﬁrming the ﬁndings of
Van Zee et al. and Hwang et al. [18, 20].
6.Associationof LobularNeoplasia with
LocalRecurrenceofDCIS
Rudloﬀ et al. sought to determine whether the associated
histologic ﬁndings of columnar cell changes, atypical ductal
hyperplasia, or lobular neoplasia aﬀected IBTR rates in
patients who underwent BCS for DCIS [30]. They state that
“the presence of concurrent proliferative lesions associated
with in situ or inﬁltrating breast carcinoma may reﬂect
underlying gene perturbations of cancer-related pathways in
the uninvolved ductal epithelium, which could be markers
of disease risk, occult disease, or, also, the tissue response
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with DCIS treated with wide local excision, with or without
radiotherapy, between 1991 and 1995, and included re-
review of all available pathology slides. Median follow-up
was 11 years (range, 0–16 years). Columnar cell changes
were present in 71 (24%), atypical ductal hyperplasia in 37
(13%), and lobular neoplasia in 41 (14%). Fifteen of 41
patients(37%)withlobularneoplasiadevelopedanIBTR;40
of 227 patients (18%) without lobular neoplasia developed
an IBTR (hazard ratio, 2.49; P = 0.001). On multivariate
analysis,5-year,10-year,and15-yearIBTRratesweretwiceas
high in women with DCIS and associated lobular neoplasia
(26%, 36%, and 55%, respectively) compared to women
with DCIS alone (14%, 19%, and 24%, respectively) (P =
0.002). In fact, the presence of lobular neoplasia and the
omission of adjuvant radiotherapy demonstrated similar
increases in IBTR rates. Columnar cell changes and atypical
ductal hyperplasia did not demonstrate increased IBTR rates
(P = 0.44 and P = 0.20, respectively). This paper found that
the presence of lobular neoplasia is associated with increased
IBTR rates in patients undergoing BCS for DCIS.
The authors hypothesized that “concurrent lobular neo-
plasia may be a phenotypic manifestation of more extensive
genetic abnormalities, resulting in a higher risk for local
recurrence.” They called for assessment of the surrounding
epitheliumtofurtherevaluatetheseﬁndingsinfutureclinical
studies of BCS for DCIS. Furthermore, the authors suggested
that if patients with DCIS and concurrent lobular neoplasia
are at higher risk, they may particularly beneﬁt from the use
of risk-reducing adjuvant therapies.
7.AssociationofMargin Widthand
Volume of DiseaseNear Marginwith
LocalRecurrenceofDCIS
Silverstein et al. found that the IBTR rate was 3% at 8
years for women who had margins at least 1cm in width
and therefore proposed that radiotherapy could be omitted
in women with DCIS who undergo BCS and have very
wide margins [31, 32]. To test this hypothesis, Rudloﬀ et al.
further examined their previous exhaustively characterized
population of 294 patients [33]. They had a median follow-
up of 11 years. They categorized patients into the same
groups used by Silverstein et al.: close or positive (margin
width <1mm), intermediate (margin width =1–9mm), and
widely clear (margin width ≥10mm). Furthermore, Rudloﬀ
et al. quantiﬁed the number of ducts involved with DCIS
at this margin width as 1 or ≥2. They combined these 2
characteristics into a measure of volume of disease near the
margin, such that each patient was categorized as: (1) widely
clear margin ≥10mm, 0 involved ducts within 10mm of
margin; (2) margin width 1 to 9mm, 1 involved duct at the
closest margin; (3) margin width <1mm, 1 involved duct
at the closest margin; and (4) margin width <10mm, ≥2
involved ducts at the closest margin.
Rudloﬀ et al. found that women with DCIS presumed to
beathigherriskofIBTR,includingthosewithhighernuclear
grade or necrosis, were more likely to receive radiation
than those presumed to be at lower risk (P<0.009).
Nonetheless, women receiving radiotherapy had lower rates
of IBTR (10-year rates without radiotherapy, 28% versus
with radiotherapy, 12%; P = 0.002), which is consistent
with randomized controlled trials [26, 34]. While adjuvant
radiotherapy beneﬁted all populations, it beneﬁted those
with closer margins more than those with wider margins.
Adjuvant radiotherapy “reduced adjusted IBTR rates by 62%
(P = 0.002) for all patients; by 83% for lesions with <1mm
margins (P = 0.002), by 70% for 1 to 9mm (P = 0.05),
and by 24% (P = 0.55) for ≥10mm.” In other words,
among patients who did not receive radiotherapy, margin
status was signiﬁcantly associated with IBTR (P = 0.02),
but receipt of radiotherapy negated any inﬂuence of margin
width on the risk of IBTR (P = 0.66). Because in this series,
radiotherapy was given according to clinical judgment in a
non-randomized fashion, Rudloﬀ et al. went on to perform
a multivariate analysis to adjust for the many other factors
that could inﬂuence the association between margin width
and added value of radiotherapy in reducing IBTR rates (age,
palpable mass, lobular neoplasia, nuclear grade, necrosis,
endocrine therapy, and number of involved ducts at closest
margin). It was unchanged.
Rudloﬀ et al. then proceeded to analyze the association
of volume of disease near margin, incorporating margin
width and number of involved ducts at the closest margin
with IBTR. Among those not receiving radiotherapy, they
found that the higher the volume of disease near the margin,
the greater the risk of IBTR, with a hazard ratio of 3.37
(P = 0.002) for IBTR among patients who had ≥2i n v o l v e d
ducts and <10mm margin width. However, among those
receiving radiotherapy, there was no increased risk of IBTR.
Stratiﬁed by volume of disease near margin, they showed
that the risk reduction associated with radiotherapy was the
greatest in those with the highest volume of disease near
the margin (hazard ratio of radiotherapy to no-radiotherapy,
0.14; P = 0.004) as compared to those with widely clear
margins (0 involved ducts within 10mm of margin; hazard
ratio of radiotherapy to no-radiotherapy, 0.60; P = 0.39).
Like others [35, 36], Rudloﬀ et al. were unable to identify
a subgroup with a very low rate of IBTR without radiother-
apy; the 10-year IBTR rate for their most favorable subgroup
(patients with wide margins and older age, and without a
palpable mass or lobular neoplasia) was 13%. Interestingly,
this rate is comparable to the IBTR rate observed in the
population that did receive radiotherapy in the Rudloﬀ study
(12%)andamongthepopulationsthatreceivedradiotherapy
in randomized controlled trials (9–20% at 8–17 years) [28,
34, 37, 38]. These ﬁndings support the concept that the
added beneﬁt of radiotherapy varies among DCIS patients
of diﬀerent risk; in other words, the beneﬁt-to-risk ratio is
not the same for all DCIS patients. For women with a higher
volumeofdiseasenearthemargin,radiotherapyisassociated
with a greater risk reduction of IBTR.
8.IntegratingClinicalandTreatment Factorsto
EstimateRiskofLocal RecurrenceofDCIS
For patients undergoing BCS for DCIS, randomized con-
trolled trials demonstrate that adjuvant radiotherapy and6 International Journal of Surgical Oncology
hormonal therapy reduce IBTR rates by 50% and 30%,
respectively [26, 34, 38]. However, because these treatments
are not without risk and because there is no observed
survival beneﬁt associated with either, expert clinicians do
not support their ubiquitous utilization [39, 40]. Some
populations may be at suﬃciently low risk of IBTR such
that the beneﬁt-to-risk ratio of adjuvant treatment is not
justiﬁed. Rudloﬀ et al. argue that “the one-size-ﬁts-all
approach of adjuvant treatment for all patients with DCIS
seems counterintuitive to both the molecular heterogeneity
of DCIS as well as the increasing trend toward individu-
alized cancer treatment” [41]. The work of Rudloﬀ et al.
discussed above certainly supports the idea that the beneﬁt-
to-risk ratio of adjuvant treatment varies with the risk of
IBTR for a woman with DCIS. In their next investigation,
Rudloﬀ et al. aimed to provide clinicians with the means
of providing that “individualized cancer treatment.” Several
clinicopathologic factors have been shown to aﬀect IBTRs
in patients undergoing BCS for DCIS. These include age,
clinical presentation, family history, tumor size, tumor
multifocality, margin status, volume of disease at the closest
margin, histologic architecture, nuclear grade, and necrosis.
Rudloﬀ et al. combine these, as well as treatment factors, to
create a clinically useful tool, a nomogram, that integrates
the information available in all of these factors in order
to estimate risk of IBTR for women undergoing BCS for
DCIS. To build this nomogram, Rudloﬀ et al. evaluated
1681 patients treated with BCS for DCIS between 1991 and
2006. Median follow-up was 5.6 years (range, 0–17.5 years).
Actuarial 5-year and 10-year IBTR rates were 9% (95%
conﬁdence interval (CI) 8–11%) and 15% (95% CI, 13–
18%), respectively.
The nomogram includes 10 parameters (age at diagnosis,
family history, initial presentation, radiotherapy, endocrine
therapy, nuclear grade, necrosis, margins, number of exci-
sions, and year of surgery), which are assigned a score
between 0 and 100. The sum of these 10 individual scores
is used to determine the 5- and 10-year risk of IBTR. Rudloﬀ
et al. provide examples: “The nomogram predicts that a 70-
year-old woman (30 points) without family history of breast
cancer (0 points), with screen-detected (0 points) DCIS with
low nuclear grade (0 points), no necrosis (0 points), and
negative margins (0 points) after one re-excision (0 points)
who does not undergo RT (100 points) or anti-estrogen
therapy (76 points) has a lower than 10% risk (total points:
206) of developing a recurrence within 10 years of BCS.
Conversely, a 40-year-old woman (75 points) with a family
history of breast cancer (30 points) and DCIS detected as
a palpable mass (34 points), who underwent one excision
(0 points) resulting in close margins (56 points), with high
nuclear grade (27 points) and necrosis (13 points), and who
defers RT (100 points) and endocrine therapy (76 points),
has about a 50% risk (total points: 411) of developing an
IBTR by 10 years.”
The nomogram was internally validated with bootstrap-
ping, and was recently validated in independent populations
byCollinsetal.[42]andY ietal.[43].Thenomogramutilizes
the many discrete factors that have been shown to aﬀect risk
ofIBTRandcombinesthemintoauser-friendlycalculatorto
estimate risk. Using these readily available factors, this tool
can assist clinicians in weighing the pros and cons of various
surgical options and adjuvant therapies for DCIS.
9. Summary
This paper summarizes the investigations of DCIS by the
Breast Surgical Service at MSKCC over the past 2 decades.
It includes papers investigating the mammographic features
of DCIS and its recurrences, the incidence and clinical
implications of SLN metastases in patients with high-risk
DCIS, the utility of preoperative MRI for Paget’s disease of
the breast, the associations of age with local recurrence and
practice patterns for treatment of DCIS, the association of
concurrent lobular neoplasia with local recurrence of DCIS,
the association of margin width and volume of disease near
margin with local recurrence of DCIS, and the creation of a
nomogramthatincorporates manyfactorssimultaneouslyto
estimate risk of IBTR of DCIS.
Abbreviations
AJCC: American Joint Commission on Cancer
BCS: Breast-conserving surgery
CI: Conﬁdence interval
DCIS: Ductal carcinoma in situ
DCIS-MI: Ductal carcinoma in situ with
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References
[ 1 ]V .L .E r n s t e r ,J .B a r c l a y ,K .K e r l i k o w s k e ,D .G r a d y ,a n d
I. C. Henderson, “Incidence of and treatment for ductal
carcinoma in situ of the breast,” Journal of the American
Medical Association, vol. 275, no. 12, pp. 913–918, 1996.
[2] P. C. Stomper and F. R. Margolin, “Ductal carcinoma in
situ: the mammographer’s perspective,” American Journal of
Roentgenology, vol. 162, no. 3, pp. 585–591, 1994.
[ 3 ]S .L .P a r k e r ,T .T o n g ,S .B o l d e n ,a n dP .A .W i n g o ,“ C a n c e r
statistics, 1996,” Ca-A Cancer Journal for Clinicians, vol. 46,
no. 1, pp. 5–27, 1996.
[4] D. D. Dershaw, A. Abramson, and D. W. Kinne, “Ductal
carcinoma in situ: mammographic ﬁndings and clinical
implications,” Radiology, vol. 170, no. 2, pp. 411–415, 1989.
[5] B. Fisher, M. Bauer, and R. Margolese, “Five-year results
of a randomized clinical trial comparing total mastectomy
and segmental mastectomy with or without radiation in the
treatment of breast cancer,” The New England Journal of
Medicine, vol. 312, no. 11, pp. 665–673, 1985.
[6] U. Veronesi, R. Saccozzi, and M. Del Vecchio, “Comparing
radical mastectomy with quadrantectomy, axillary dissection,
and radiotherapy in patients with small cancers of the breast,”
The New England Journal of Medicine, vol. 305, no. 1, pp. 6–11,
1981.International Journal of Surgical Oncology 7
[ 7 ]L .L i b e r m a n ,K .J .V a nZ e e ,D .D .D e r s h a w ,E .A .M o r r i s ,A .
F. Abramson, and B. Samli, “Mammographic features of local
recurrence in women who have undergone breast-conserving
therapy for ductal carcinoma in situ,” American Journal of
Roentgenology, vol. 168, no. 2, pp. 489–493, 1997.
[ 8 ]H .S .C o d y ,N .K l a u b e r - D e M o r e ,P .I .B o r g e n ,a n dK .J .V a n
Zee, “Is it really duct carcinoma in situ?” Annals of Surgical
Oncology, vol. 8, no. 8, pp. 617–619, 2001.
[9] H. S. Cody and K. J. Van Zee, “Point: sentinel lymph node
biopsy is indicated for patients with DCIS,” Journal of the
NationalComprehensiveCancerNetwork,vol.1,no.2,pp.199–
206, 2003.
[10] M. D. Lagios and M. J. Silverstein, “Sentinel node biopsy for
patients with DCIS: a dangerous and unwarranted direction,”
Annals of Surgical Oncology, vol. 8, no. 4, pp. 275–277, 2001.
[11] S. A. McLaughlin, M. J. Wright, K. T. Morris et al., “Prevalence
of lymphedema in women with breast cancer 5years after
sentinel lymph node biopsy or axillary dissection: patient
perceptions and precautionary behaviors,” Journal of Clinical
Oncology, vol. 26, no. 32, pp. 5220–5226, 2008.
[12] S. A. McLaughlin, M. J. Wright, K. T. Morris et al., “Prevalence
of lymphedema in women with breast cancer 5 years after
sentinel lymph node biopsy or axillary dissection: objective
measurements,” Journal of Clinical Oncology, vol. 26, no. 32,
pp. 5213–5219, 2008.
[13] N. Klauber-DeMore, L. K. Tan, L. Liberman et al., “Sentinel
lymph node biopsy: is it indicated in patients with high-risk
ductal carcinoma-in-situ and ductal carcinoma-in-situ with
microinvasion?” Annals of Surgical Oncology,v o l .7 ,n o .9 ,p p .
636–642, 2000.
[14] K. H. Moore, K. J. Sweeney, M. E. Wilson et al., “Outcomes for
women with ductal carcinoma-in-situ and a positive sentinel
node: a multi-institutional audit,” Annals of Surgical Oncology,
vol. 14, no. 10, pp. 2911–2917, 2007.
[15] A. C. Ascensao, M. S. J. Marques, and M. Capitao-Mor,
“Paget’s disease of the nipple: clinical and pathological review
of 109 female patients,” Dermatologica, vol. 170, no. 4, pp.
170–179, 1985.
[16] J. H. Yim, M. R. Wick, G. W. Philpott, J. A. Norton, and G. M.
Doherty,“UnderlyingpathologyinmammaryPaget’sdisease,”
Annals of Surgical Oncology, vol. 4, no. 4, pp. 287–292, 1997.
[17] M. Morrogh, E. A. Morris, L. Liberman, K. Van Zee, H. S.
Cody, and T. A. King, “MRI identiﬁes otherwise occult disease
in select patients with Paget disease of the nipple,” Journal of
the American College of Surgeons, vol. 206, no. 2, pp. 316–321,
2008.
[18] K. J. Van Zee, L. Liberman, B. Samli et al., “Long term follow-
up of women with ductal carcinoma in situ treated with
breast-conserving surgery: the eﬀect of age,” Cancer, vol. 86,
no. 9, pp. 1757–1767, 1999.
[19] U. Veronesi, A. Luini, M. Del Vecchio et al., “Radiotherapy
afterbreast-preservingsurgeryinwomenwithlocalizedcancer
of the breast,” The New England Journal of Medicine, vol. 328,
no. 22, pp. 1587–1591, 1993.
[20] E. S. Hwang, B. Samli, K. N. Tran, P. P. Rosen, P. I. Borgen,
and K. J. Van Zee, “Volume of resection in patients treated
with breast conservation for ductal carcinoma in situ,” Annals
of Surgical Oncology, vol. 5, no. 8, pp. 757–763, 1998.
[21] A. Recht, J. L. Connolly, S. J. Schnitt et al., “The eﬀect of
young age on tumor recurrence in the treated breast after
conservative surgery and radiotherapy,” International Journal
of Radiation Oncology Biology Physics, vol. 14, no. 1, pp. 3–10,
1988.
[22] J. M. Kurtz, J. Jacquemier, R. Amalric et al., “Why are local
recurrences after breast-conserving therapy more frequent in
younger patients?” Journal of Clinical Oncology, vol. 8, no. 4,
pp. 591–598, 1990.
[23] A. J. Nixon, D. Neuberg, D. F. Hayes et al., “Relationship of
patient age to pathologic features of the tumor and prognosis
for patients with stage I or II breast cancer,” Journal of Clinical
Oncology, vol. 12, no. 5, pp. 888–894, 1994.
[24] A. Ho, A. Goenka, N. Ishill et al., “The eﬀe c to fa g ei n
the outcome and treatment of older women with ductal
carcinoma in situ,” Breast, vol. 20, no. 1, pp. 71–77, 2010.
[25] B. D. Smith, G. L. Smith, A. Hurria, G. N. Hortobagyi, and T.
A. Buchholz, “Future of cancer incidence in the United States:
burdens upon an aging, changing nation,” Journal of Clinical
Oncology, vol. 27, no. 17, pp. 2758–2765, 2009.
[26] B. Fisher, S. Land, E. Mamounas, J. Dignam, E. R. Fisher, and
N. Wolmark, “Prevention of invasive breast cancer in women
with ductal carcinoma in situ: an update of the National
Surgical Adjuvant Breast and Bowel Project experience,”
Seminars in Oncology, vol. 28, no. 4, pp. 400–418, 2001.
[27] J. Houghton, “Radiotherapy and tamoxifen in women with
completely excised ductal carcinoma in situ of the breast in
the UK, Australia, and New Zealand: randomised controlled
trial,” The Lancet, vol. 362, no. 9378, pp. 95–102, 2003.
[28] J. Cuzick, I. Sestak, S. E. Pinder et al., “Eﬀect of tamoxifen and
radiotherapy in women with locally excised ductal carcinoma
in situ: long-term results from the UK/ANZ DCIS trial,” The
Lancet Oncology, vol. 12, no. 1, pp. 21–29, 2011.
[29] C. Correa, P. McGale, C. Taylor et al., “Overview of the
randomized trials of radiotherapy in ductal carcinoma in
situ of the breast,” Journal of the National Cancer Institute—
Monographs, vol. 2010, no. 41, pp. 162–177, 2010.
[30] U. Rudloﬀ,E .B r o g i ,J .P .B r o c k w a ye ta l . ,“ C o n c u r r e n t
lobular neoplasia increases the risk of ipsilateral breast cancer
recurrence in patients with ductal carcinoma in situ treated
with breast-conserving therapy,” Cancer, vol. 115, no. 6, pp.
1203–1214, 2009.
[31] M. J. Silverstein, “The University of Southern California/Van
Nuys prognostic index for ductal carcinoma in situ of the
breast,” American Journal of Surgery, vol. 186, no. 4, pp. 337–
343, 2003.
[32] M.J.Silverstein,M.D.Lagios,S.Groshenetal.,“Theinﬂuence
of margin width on local control of ductal carcinoma in situ
of the breast,” The New England Journal of Medicine, vol. 340,
no. 19, pp. 1455–1461, 1999.
[33] U. Rudloﬀ, E. Brogi, A. S. Reiner et al., “The inﬂuence of
margin width and volume of disease near margin on beneﬁt
ofradiationtherapyforwomenwithDCIStreatedwithbreast-
conservingtherapy,”AnnalsofSurgery,vol.251,no.4,pp.583–
591, 2010.
[34] N. Bijker, P. Meijnen, J. L. Peterse et al., “Breast-conserving
treatment with or without radiotherapy in ductal carcinoma-
in-situ: ten-year results of european organisation for research
and treatment of cancer randomized phase III trial 10853—
a study by the EORTC breast cancer cooperative group and
EORTC radiotherapy group,” Journal of Clinical Oncology, vol.
24, no. 21, pp. 3381–3387, 2006.
[35] L. Hughes, M. Wang, D. Page et al., “Five year results of
intergroup study E5194: local excision alone (without radia-
tion treatment) for selected patients with ductal carcinoma in
situ (DCIS),” Breast Cancer Research and Treatment, vol. 100,
supplement 1, p. S15, 2006.
[36] J. S. Wong, C. M. Kaelin, S. L. Troyan et al., “Prospective study
of wide excision alone for ductal carcinoma in situ of the8 International Journal of Surgical Oncology
breast,” Journal of Clinical Oncology, vol. 24, no. 7, pp. 1031–
1036, 2006.
[37] I. L. Wapnir, J. J. Dignam, B. Fisher et al., “Long-term
outcomes of invasive ipsilateral breast tumor recurrences after
lumpectomy in NSABP B-17 and B-24 randomized clinical
trials for DCIS,” Journal of the National Cancer Institute, vol.
103, no. 6, pp. 478–488, 2011.
[38] L. Holmberg, H. Garmo, B. Granstrand et al., “Absolute risk
reductions for local recurrence after postoperative radiother-
apy after sector resection for ductal carcinoma in situ of the
breast,” Journal of Clinical Oncology, vol. 26, no. 8, pp. 1247–
1252, 2008.
[39] E. Ceilley, R. Jagsi, S. Goldberg, L. Kachnic, S. Powell, and
A. Taghian, “The management of ductal carcinoma in situ in
North America and Europe: results of a survey,” Cancer, vol.
101, no. 9, pp. 1958–1967, 2004.
[40] T. W. F. Yen, H. M. Kuerer, R. A. Ottesen et al., “Impact of ran-
domized clinical trial results in the National Comprehensive
Cancer Network on the use of tamoxifen after breast surgery
for ductal carcinoma in situ,” Journal of Clinical Oncology, vol.
25, no. 22, pp. 3251–3258, 2007.
[41] U. Rudloﬀ,L .M .J a c k s ,J .I .G o l d b e r ge ta l . ,“ N o m o g r a mf o r
predicting the risk of local recurrence after breast-conserving
surgery for ductal carcinoma in situ,” Journal of Clinical
Oncology, vol. 28, no. 23, pp. 3762–3769, 2010.
[42] L. C. Collins, N. Achacoso, Z. Sharafali et al., “Predictors
of local recurrence (LR) in patients with ductal carcinoma
in situ (DCIS) treated by breast conserving therapy (BCT):
Value of the Memorial Sloan-Kettering (MSK) nomogram,” in
Proceedingsofthe101stAnnualMeetingoftheUnitedStatesand
Canadian Academy of Pathology, March 2012.
[43] M. Yi, F. Meric-Bernstam, H. M. Kuerer et al., “Evaluation
of a breast cancer nomogram for predicting risk of ipsilateral
breast tumor recurrences in patients with ductal carcinoma in
situ after local excision,” Journal of Clinical Oncology, vol. 30,
no. 6, pp. 600–607, 2012.